| Literature DB >> 27007977 |
Polina Mamoshina1, Armando Vieira2, Evgeny Putin1, Alex Zhavoronkov1.
Abstract
Increases in throughput and installed base of biomedical research equipment led to a massive accumulation of -omics data known to be highly variable, high-dimensional, and sourced from multiple often incompatible data platforms. While this data may be useful for biomarker identification and drug discovery, the bulk of it remains underutilized. Deep neural networks (DNNs) are efficient algorithms based on the use of compositional layers of neurons, with advantages well matched to the challenges -omics data presents. While achieving state-of-the-art results and even surpassing human accuracy in many challenging tasks, the adoption of deep learning in biomedicine has been comparatively slow. Here, we discuss key features of deep learning that may give this approach an edge over other machine learning methods. We then consider limitations and review a number of applications of deep learning in biomedical studies demonstrating proof of concept and practical utility.Entities:
Keywords: RBM; artificial intelligence; biomarker development; deep learning; deep neural networks; genomics; transcriptomics
Mesh:
Substances:
Year: 2016 PMID: 27007977 DOI: 10.1021/acs.molpharmaceut.5b00982
Source DB: PubMed Journal: Mol Pharm ISSN: 1543-8384 Impact factor: 4.939